A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-09

Study Completion Date

2031-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-A101 to treat participants with knee osteoarthritis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

NCT01430559

Osteoarthritis of the Knee

COMPLETED NA

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

NCT03513016

Osteoarthritis, Knee

COMPLETED PHASE1

Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

NCT01111045

Osteoarthritis of the Knee

COMPLETED PHASE2

A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee

NCT04229225

Knee Osteoarthritis

COMPLETED PHASE1

Efficacy and Safety of TongBi Capsule in Patients With Knee Osteoarthritis

NCT03418155

Knee Osteoarthritis

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is divided into two phases: Phase Ia and Phase Ib . Phase Ia is a randomized, single-blind study . Phase Ib is a randomized, double blind, parallel assignment study.

BBM-A101 is an AAVbased gene therapy that delivers a therapeutic gene cassette into knee for the treatment of knee osteoarthritis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

The masking subjects in the Ia phase is participant , but the phase Ib study is double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm of Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo(phase Ia)

Placebo

Intervention Type DRUG

Placebo（phase Ib）

Arm of BBM-A101

Group Type EXPERIMENTAL

BBM-A101

Intervention Type DRUG

Single-dose intra-articular （IA）injection （2ml）(phase Ia)

Low dose group， Middle dose group； High dose group； Control group ：Placebo

BBM-A101

Intervention Type DRUG

Single-dose intra-articular （IA）injection （2ml）(phase Ib) Low dose group， High dose group

Control group ：Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BBM-A101

Single-dose intra-articular （IA）injection （2ml）(phase Ia)

Low dose group， Middle dose group； High dose group； Control group ：Placebo

Intervention Type DRUG

Placebo

Placebo(phase Ia)

Intervention Type DRUG

BBM-A101

Single-dose intra-articular （IA）injection （2ml）(phase Ib) Low dose group， High dose group

Control group ：Placebo

Intervention Type DRUG

Placebo

Placebo（phase Ib）

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants with moderate knee osteoarthritis .
2. The knee joint was evaluated as having Kellgren-Lawrence grade 2 or 3.
3. The Body Mass Index (BMI) ranges from 18.0 to 35.0 kg/m2 (including the boundary values).
4. Lower titers of antibodies binding to the BBM-A101 capsid in the blood.
5. Participants who had received adequate treatment with conventional medications previously, experienced recurrence or aggravation of target knee arthritis after discontinuation of medication, and still had moderate pain; during the screening period, the WOMAC pain score of the target knee was ≥ 8 .
6. From the time of screening to 52 weeks after dosing , the participants had no intention of having children and voluntarily took effective contraceptive measures, and there were no plans for sperm donation or ova donation.
7. Voluntarily sign the informed consent form and be able to complete the research as required by the clinical trial protocol.

\-

Exclusion Criteria

1. There is a possibility of secondary knee osteoarthritis, or the knee joint symptoms may not be caused by knee osteoarthritis, or there may be other medical histories of diseases that other researchers believe could potentially lead to knee osteoarthritic inflammation.
2. History of lumbar dischernaiation, accompanied by lower limb nerve symptoms that may affect the assessment of the study.
3. Participants who are unable or unwilling to undergo MRI examination, or who have contraindications to MRI.
4. Participants who are unable or unwilling to undergo joint fluid extraction.
5. During the screening period and before dosing, there were clinically significant abnormal values in the laboratory tests, and the researchers believed that these might pose risks to the participants in the clinical trial.
6. Those with positive results for hepatitis B virus surface antigen or hepatitis B virus deoxyribonucleic acid or hepatitis C virus ribonucleic acid test or human immunodeficiency virus antibody or Treponema pallidum antibody.
7. Currently undergoing treatment for hepatitis B and hepatitis C.
8. Participants who had persistent chronic or active infections within the previous 4 weeks were selected.
9. Participants who had coagulation disorders (such as hemophilia) or existing medical conditions that require anticoagulation therapy and make knee joint injection impossible.
10. Having or having had cancer or malignant tumors
11. Having received genetic therapy or stem cell therapy before screening or having plans for genetic therapy or stem cell therapy during the study period.
12. Any history of vaccination within 30 days prior to dosing or any vaccination schedule within 30 days after dosing.
13. Screening will be conducted on female participants who are pregnant or breastfeeding or whose HCG test result is positive; or who have plans to get pregnant within the next 52 w.
14. History of alcohol addiction or drug dependence, or inability to limit alcohol consumption during the research process.
15. Participants had any mental disorders that might affect the assessment of the study.
16. Having other conditions that the investigator consider unsuitable for participation in the study.

\-

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No